By Rob Curran
Oncology drug developer Kintara Therapeutics said a brain-cancer treatment candidate showed scant promise in an early-stage study, convincing it to suspend development and concentrate its resources on a breast-cancer treatment candidate.
The San Diego development-stage biopharmaceutical company said its VAL-083 product failed to perform better than the current standards of care in glioblastoma, according to preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment study. Following the study, Kintara is suspending the development of VAL-083 and turning its focus to its second program, REM-001. The company added that it will evaluate strategic options to maximize shareholder value.
Kintara anticipates enrolling the first patient for a 15-patient study of the REM-001 product for treatment of cutaneous metastatic breast cancer by the end of the year.
In June, the biopharmaceutical company said it received a $2 million grant from the National Institute of Health’s Small Business Innovation Research program to support the clinical development of REM-001, a photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer.
Kintara expects to receive the full results of the glioblastoma study at the end of the first quarter or the beginning of the second quarter of 2024. At that stage, it will weigh options for its VAL-083 program.
Write to Rob Curran at [email protected]
Read the full article here
